MDT Q4 2026 Earnings Analysis
Medtronic delivered FY26 revenue of $36.4B (+5.8% organic) with adjusted EPS of $5.53, driven by strong CAS growth (78%), Symplicity momentum ($100M annualized), and Hugo robotics expansion, guiding FY27 organic growth of 6.75%-7.25% despite $250M tariff headwinds.
Key Metrics
Wichtigste Erkenntnisse
- CAS delivered 78% growth with 124% U.S. growth; Symplicity annualizing at $100M with doubled procedure volumes post-NCD.
- Neuroscience positioned to accelerate with Stealth AXiS launch, Hugo robotics expanding to urology/general surgery, and Altaviva showing 3x sequential growth in active implanters.
- FY27 guidance includes $250M tariff headwind, 2% M&A dilution, and full-year Diabetes business pending separation timing.
Anhören auf
Verfügbar in
Transcript
// Full episode scriptBeta Finch Podcast Script: Medtronic Q4 2026 Earnings
Welcome back to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're unpacking Medtronic's fourth quarter 2026 results, and folks, this is a company that's clearly hitting its stride. Before we dive in, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Thanks Alex, and wow - where do we even start with Medtronic? These numbers are impressive. The company just posted $9.8 billion in Q4 revenue, up nearly 10% reported and 6.6% organically. But here's what really caught my attention - this caps off their strongest annual performance in a decade.
That's right, Jordan. For the full fiscal year, they hit $36.4 billion in revenue with 8.4% reported growth and 5.8% organic growth. CEO Geoff Martha was clearly proud of these results, calling it a reflection of their "commitment to operational rigor" while investing in durable growth. But let's talk about what's really driving this performance.
The star of the show has got to be their Cardiac Ablation Solutions business - or CAS. This division delivered 78% worldwide growth and gained 8 points of U.S. market share. Their PFA technology saw 145% global growth, with their Sphere-9 catheter continuing to show "broad versatility," as Martha put it.
And here's what's really exciting about CAS - they're still in the "early innings," as CFO Thierry Pieton noted. The company increased their installed base by 40% just in the fourth quarter alone. They're now annualizing over $2 billion in revenue and are on track to hit that $2 billion trailing mark in the first quarter of fiscal 2027. That's massive scale in a high-growth market.
What I found fascinating was Martha's comment about "completely surrounding the electrophysiology space." They're not just selling one product - they're building an entire ecosystem. They launched Sphere-9 in Japan, got FDA approval for a U.S. VT pivotal trial, and even announced two targeted investments in ICE catheter technology this morning.
Speaking of investments, let's talk about their capital allocation strategy because this is where you really see the company's long-term vision. In Q4 alone, they closed or announced nearly $2 billion in additional investments through M&A and venture deals. They acquired CathWorks for their AI-powered FFRangio system, announced plans to buy Scientia for neurovascular guidewire tech, and made investments in everything from chronic pain management to pulmonary artery denervation.
That's a great point, Alex. And it's not just about buying technology - it's about strategic positioning. Take their Symplicity Spyral system for treating hypertension. This business is now annualizing at $100 million, and they've doubled their weekly procedure volumes since getting the NCD coverage decision. Martha emphasized that 18 million Americans still have uncontrolled hypertension despite multiple medications - that's a massive addressable market.
Let's shift to the numbers that investors will be watching closely. For fiscal 2027, Medtronic is guiding to organic revenue growth of 6.75% to 7.25%. Now, there's an extra selling week baked into that, which adds about 125 basis points, but even adjusting for that, we're looking at solid mid-single-digit growth acceleration.
The guidance is particularly interesting because of how they're handling the MiniMed diabetes business. They completed the IPO in March, but they're conservatively including the full year in their 2027 guidance since they don't know exactly when the separation will be complete. If it happens earlier than expected, there could be upside to the guidance.
There are some headwinds to watch though. Tariffs are expected to impact COGS by about $250 million in fiscal 2027, and they're factoring in 2% dilution from M&A activities. Plus, there are increased fuel and transportation costs due to Middle East conflicts.
But here's what I think is really telling about management's confidence - their operating margin is expected to increase by 60 basis points in fiscal 2027, driven by operating leverage and the removal of those Blackstone milestone payments they had this year. That shows they're not just growing the top line; they're doing it profitably.
During the Q&A, there were some great insights into specific business performance. One analyst asked about their TAVR business, which has faced some pressure from low-risk data earlier this year. Martha was pretty direct - the business has stabilized over the last 8-10 weeks, and while there was a U.S.-specific slowdown, the international business remained strong.
I also appreciated the question about their surgical robotics platform, Hugo. Martha noted that Hugo contributed to Q4 growth and that they've submitted for FDA clearance for general surgery and gynecologic indications. Their Touch Surgery digital platform now has over 1,400 installations, up 30% sequentially. This is clearly becoming a meaningful part of their surgical ecosystem.
One thing that stood out was their China strategy discussion. Despite all the VBP pressures - those volume-based procurement programs - Martha said China remains profitable and growing at the corporate average. He emphasized that the "worst is behind us" on VBP, and they've been able to increase procedures while managing costs.
Looking forward, what excites me most is the breadth of their growth drivers. It's not just one or two products carrying the company. You've got CAS still in early innings, Symplicity ramping up, Hugo gaining traction, their Altaviva device for urinary incontinence showing 3x growth in active implanters, and their Stealth AXiS navigation system getting strong physician feedback.
And let's not forget their core businesses are performing well too. Cardiac Rhythm Management delivered 5% growth with strong momentum in defibrillation and pacing therapies. Their Neuroscience portfolio, where they're the number one player across every segment, is positioned for acceleration with new platform launches.
The leadership transition they announced is also worth noting. Brett Wall is retiring after 25 years, and Dr. Kweli Thompson is stepping in to lead the Neuroscience portfolio. Thompson was previously running their CRM business, so he's got a proven track record in a high-performing division.
As we wrap up, what's your overall take on Medtronic's position, Jordan?
I think this is a company that's successfully transformed itself from a slower-growth medical device giant into a more focused, innovation-driven growth story. They're making smart investments in high-growth markets, their core businesses are stable and growing, and they're building platforms rather than just selling individual products. The breadth of their growth drivers gives me confidence this isn't just a one-quarter story.
I completely agree. The combination of strong execution, strategic focus through portfolio optimization, and aggressive but targeted capital deployment seems to be paying off. With 6-7% organic growth guidance for 2027 and multiple growth drivers still in early stages, this looks like a sustainable acceleration story.
Before we sign off, I need to remind everyone that everything we've discussed today is AI-generated analysis for educational purposes only. Past performance doesn't guarantee future results. Please do your own due diligence before making any investment decisions.
That's right, Jordan. Thanks for listening to Beta Finch, and we'll see you next time for another AI-powered earnings breakdown. Until then, keep learning and stay curious about the markets!